We thus treated Jurkat T-ALL cells with increasing doses of drugs targeting mTOR (AZD8055), PI3K (CAL-101), AKT (MK-2206), p70 S6 Kinase (PF-4708671) and SGK (GSK650394) alone or in combination with CsA. Here, AKT1 is linked to acute lymphoblastic leukemia.